Theophylline sustained-release tablets

Theophylline has a strong direct relaxant effect on smooth muscles such as the respiratory tract, and also strengthens myocardial contractility, increases cardiac output and has a diuretic effect. The sustained-release excipients allow the drug to be released slowly and evenly in the gastrointestinal tract, and the blood drug concentration is stable after absorption, with small toxic and side effects, long drug effect time and high bioavailability. This product can stabilize and maintain effective blood drug concentration for more than 12 hours with a single administration, extending the dosing interval, reducing the number of dosing times, making it convenient to take, and can effectively prevent nocturnal asthma attacks.

The main ingredient of this product is theophylline. Its chemical name is 1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione monohydrate.

This product is white tablets.

It is mainly used to treat bronchial asthma, cardiac asthma, emphysema, chronic bronchitis, etc.; it can also be used for diuresis and swelling reduction of cardiogenic and renal edema.

Oral administration: 1-2 tablets at a time, once every 12 hours. Take after meals. The tablets should be taken whole to ensure good efficacy.

The side effects are mild, with occasional nausea, vomiting or mild gastrointestinal discomfort, which disappear on their own after stopping the drug.

It is contraindicated for those who are allergic to theophylline drugs.

Precautions for children: The plasma clearance rate of newborns may be reduced and the serum concentration may increase, so it should be used with caution. The safety and effectiveness of this product for children under 12 years old are still uncertain. Please follow the doctor's advice when using it for children over 12 years old. Precautions for pregnancy and lactation: This product can pass through the placental barrier and can also be secreted into breast milk and excreted with breast milk. Pregnant women, parturient women and lactating women should use it with caution. Precautions for the elderly: The plasma clearance rate of the elderly is reduced and the potential toxicity is increased. Patients over 55 years old should use it with caution.

1. Diltiazem and verapamil can interfere with the metabolism of theophylline in the liver. When used in combination with this product, the blood concentration and toxicity of this product will be increased. 2. Cimetidine can reduce the liver clearance rate of this product. When used in combination, it can increase the serum concentration and (or) toxicity of theophylline. 3. Certain antibacterial drugs, such as erythromycin, roxithromycin, clarithromycin of macrolides, enoxacin, ciprofloxacin, ofloxacin, levofloxacin, clindamycin, lincomycin of quinolones, etc., can reduce the clearance rate of theophylline and increase its blood concentration, especially erythromycin and enoxacin. When theophylline is used in combination with the above drugs, the dosage should be appropriately reduced. 4. Phenobarbital, phenytoin, and rifampicin can induce liver enzymes and accelerate the liver clearance rate of theophylline; theophylline also interferes with the absorption of phenytoin. The plasma concentrations of both decrease. The dosage should be adjusted when used in combination. 5. When used in combination with lithium salts, the renal excretion of lithium can be increased. Affect the effect of lithium salts. 6. When used in combination with mexiletine, the clearance of theophylline can be reduced, the concentration of theophylline in plasma can be increased, and the dosage needs to be adjusted. 7. When used in combination with caffeine or other xanthine drugs, their effects and toxicity can be increased.

Keep sealed.

0.1g

24 months

Jilin Yatai Pharmaceutical Co., Ltd.

• Founded in:

  1999-09-07

• Address:

  No. 8000, Beiyuanda Street, High-tech Development Zone, Changchun City, Jilin Province

• Tax NO.:

  91220000715393231E

• Registered Funds:

  83.150448 million yuan

• Website:

  Log in to view

• Email:

  Log in to view